| Entry |
|
|---|
| Name |
Osimertinib mesylate (USAN);
Osimertinib mesilate (JAN);
Tagrisso (TN)
|
|---|
| Product |
|
|---|
| Formula |
C28H33N7O2. CH4SO3
|
|---|
| Exact mass |
595.2577
|
|---|
| Mol weight |
595.713
|
|---|
| Structure |
   |
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
DG01633 CYP3A substrate
Transporter inhibitor
DG02862 ABCG2 (BCRP) inhibitor
|
|---|
| Remark |
| Therapeutic category: | 4291 |
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Disease |
Non-small cell lung cancer (EGFR mutation positive) [DS: H00014] |
|---|
| Target |
|
|---|
| Network |
| N10006 | Third-generation tyrosine kinase inhibitor to EGFR mutation |
|
|---|
| Pathway |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance |
|
|---|
| Metabolism |
|
|---|
| Interaction |
Transporter inhibition: ABCG2 [HSA: 9429]
 |
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XE Protein kinase inhibitors
L01XE35 Osimertinib
D10766 Osimertinib mesylate (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Osimertinib
D10766 Osimertinib mesylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D10766 Osimertinib mesylate (USAN); Osimertinib mesilate (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR [HSA_VAR:1956v3]
D10766 Osimertinib mesylate (USAN) <JP/US>
Antineoplastics [br08340.html]
D10766
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10766
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10766
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10766
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10766
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10766
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 42
1 C8y C 15.8155 -13.2242
2 N5x N 15.8155 -14.6236
3 C8y C 17.0050 -15.3233
4 N5x N 18.2645 -14.6236
5 C8x C 18.2645 -13.2242
6 C8x C 17.0050 -12.5245
7 C8y C 14.6003 -12.5262
8 C8x C 14.6279 -11.1251
9 N4y N 13.3039 -10.6659
10 C8y C 12.4581 -11.7832
11 C8y C 13.2592 -12.9328
12 C8x C 11.0637 -11.9021
13 C8x C 10.4694 -13.1690
14 C8x C 11.2707 -14.3187
15 C8x C 12.6650 -14.1998
16 C1a C 12.8886 -9.2966
17 N1b N 16.9878 -16.7226
18 C8y C 18.2037 -17.4448
19 C8x C 18.1866 -18.8219
20 C8y C 19.3897 -19.5366
21 C8y C 20.6803 -18.8521
22 C8x C 20.6274 -17.4750
23 C8y C 19.4243 -16.7602
24 O2a O 19.3720 -15.3934
25 C1a C 20.6720 -14.7043
26 N1b N 19.3724 -20.9210
27 C5a C 18.1606 -21.6005
28 C2b C 16.9914 -20.9059
29 O5a O 18.1425 -23.0191
30 C2a C 15.7749 -21.5882
31 N1c N 21.8239 -19.5735
32 C1b C 23.0438 -18.8898
33 C1a C 21.8058 -20.9907
34 C1b C 24.2317 -19.5961
35 N1c N 25.4394 -18.9193
36 C1a C 26.6533 -19.6413
37 C1a C 25.3871 -17.4925
38 S4a S 25.1915 -11.9653
39 O1d O 25.1915 -10.5658
40 O1d O 25.1915 -13.3647
41 C1a C 23.7921 -11.9653
42 O1d O 26.5909 -11.9653
BOND 44
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 1 7 1
8 7 8 2
9 8 9 1
10 9 10 1
11 10 11 1
12 7 11 1
13 10 12 2
14 12 13 1
15 13 14 2
16 14 15 1
17 11 15 2
18 9 16 1
19 3 17 1
20 17 18 1
21 18 19 2
22 19 20 1
23 20 21 2
24 21 22 1
25 22 23 2
26 18 23 1
27 23 24 1
28 24 25 1
29 20 26 1
30 26 27 1
31 27 28 1
32 27 29 2
33 28 30 2
34 21 31 1
35 31 32 1
36 31 33 1
37 32 34 1
38 34 35 1
39 35 36 1
40 35 37 1
41 38 39 2
42 38 40 2
43 38 41 1
44 38 42 1
|
|---|
